The Disease Interception Accelerator and Janssen Pharmaceuticals, Inc. entered into a research agreement with Washington University and award-winning immunologist Emil Unanue, M.D., Paul & Ellen Lacy Professor of Pathology & Immunology at Washington University, to identify the root cause of type 1 diabetes and enable the development of interventions that halt progression to disease.
Collaborating in more than 150 markets.
By clicking on a link below, you may enter a different part of this website, or a website outside of Janssen.com.
These sections or websites are governed by their own Legal and Privacy Policies.
Europe, Middle East & Africa (EMEA)
Washington University Research Alliance
Research Alliance Marks Innovative Collaboration in Type 1 Diabetes